NWMP
CORT icon

Noble Wealth Management PBC’s Corcept Therapeutics CORT Stock Holding History

Noble Wealth Management PBC’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.04K Hold
9
– – ﹤0.01% 672
2026
Q2 		$783 Buy
+9
New +$543 ﹤0.01% 745

Other funds holding CORT

VFP
Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
RA
Riversedge Advisors Wilmington, Delaware $813M AUM 18.09% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return

Noble Wealth Management PBC's CORT Position: Q3 2026 in Review

Noble Wealth Management PBC held its Corcept Therapeutics (CORT) position steady in Q3 2026 at 9 shares worth $1.04K. The position accounts for ﹤0.01% of the portfolio, ranked #672.

Noble Wealth Management PBC first reported a position in CORT in Q2 2026 and has held it in 2 quarters since. 12 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Noble Wealth Management PBC held 9 shares of Corcept Therapeutics worth $1.04K as of Q3 2026.
  • Noble Wealth Management PBC left its Corcept Therapeutics share count unchanged in Q3 2026.
  • Corcept Therapeutics made up ﹤0.01% of Noble Wealth Management PBC's portfolio in Q3 2026, its #672 holding.
  • Noble Wealth Management PBC first reported a position in Corcept Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 12 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Noble Wealth Management PBC's 13F filing for Q3 2026, filed 1 Oct 2026.